Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

796.93 -22.45 (-2.74%)
Streaming Delayed Price Updated: 9:42 AM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Eli Lilly Sets Ambitious Sustainability Goals Despite Headwinds
Eli Lilly's prescription for growth and sustainability includes a strong drug pipeline, revenue growth and energy investments. 
Via Investor's Business Daily
Which S&P500 stocks are moving before the opening bell on Friday?
Get insights into the top gainers and losers in the S&P500 index of Friday's pre-market session. 
Via Chartmill
Eli Lilly Says Verzenio Reduced Risk of Death In Late-Stage Trial In Some Breast Cancer Patients
Via Stocktwits
Eli Lilly Makes A Bold Claim For Its Biggest Cancer Drug
Eli Lilly said Friday a combo using Verzenio cut the risk of death by nearly 16% over two years for breast cancer patients. 
Via Investor's Business Daily
Eli Lilly vs. Viking Therapeutics Stock: Which Is the Best Growth Opportunity, According to Wall Street?
These stocks have climbed in the triple digits over the past few years. 
Via The Motley Fool
Eli Lilly Says Oral GLP-1 Drug Reduced Blood Sugar Levels In Two Late-Stage Trials
Via Stocktwits
Revolution Medicines, Disc Medicine, Regeneron Stocks Jump After-Hours As FDA Fast-Tracks 9 Drugs Under New Review Program
The FDA’s new National Priority Voucher pilot helps with faster drug reviews, cutting timelines from nearly a year to weeks. 
Via Stocktwits
Eli Lilly, Novo Nordisk Stocks Fall After-Hours As Trump Pledges Swift Price Cuts For ‘Fat-Loss Drugs’
Novo Nordisk is also continuing discussions with the administration under the Most Favored Nation policy aimed at linking U.S. drug costs to global benchmarks. 
Via Stocktwits
Topics Economy Government
Global Markets Brace for Impact as Investor Risk Aversion Escalates Amidst Geopolitical Tensions and Economic Headwinds
Global financial markets are currently navigating a treacherous landscape marked by a pronounced surge in investor risk aversion. As of October 16, 2025, a potent cocktail of persistent geopolitical... 
Via MarketMinute
Topics Bonds Economy World Trade
Eli Lilly, Novo Nordisk, Hims & Hers Health Shares Move Lower After Trump Calls Out 'Fat-Loss Drugs'
Shares of Eli Lilly and Novo Nordisk move lower in Thursday's after-hours session after President Trump indicated weight-loss drugs are going to go down in price. 
Via Benzinga
Topics Government
Chesapeake Sells 9,900 Eli Lilly (LLY) Shares Worth $7.7 Million
Via The Motley Fool
Topics Regulatory Compliance
2 Pharmaceutical Growth Stocks to Buy Now and Hold for Decades
These companies are investing heavily into their pipelines and the payoff for long-term investors can be substantial. 
Via The Motley Fool
Did Viking Therapeutics Just Say "Checkmate" to Eli Lilly?
The smaller drugmaker is looking to disrupt a fast-growing market. 
Via The Motley Fool
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.
Investors should be able to count on these stocks to deliver steady and growing income over the long term. 
Via The Motley Fool
Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead
Novo Nordisk’s $4.7B Akero deal boosts its metabolic health pipeline, targeting Eli Lilly’s lead in obesity and liver disease treatments 
Via MarketBeat
Topics World Trade
Chesapeake Asset Management Begins Investing in Ryder System. Is the Stock a Buy?
Via The Motley Fool
Topics Economy Regulatory Compliance
Eli Lilly's Oral Weight Loss Drug Shows Superiority Over Two Approved Drugs
Orforglipron meets key endpoints in Phase 3 trials, showing A1C reduction, weight loss, and cardiovascular benefits for type 2 diabetes. 
Via Benzinga
Eli Lilly Stock: Elevated Momentum, Strong Analyst Backing, Near-Term Earnings Focus
Eli Lilly's stock shows robust momentum and strong analyst support, driven by solid fundamentals and positive market sentiment, while upcoming earnings releases remain a focal point for investors. 
Via Talk Markets
Meet the 1.4% Yield Dividend Stock That Could Soar in 2026
The company is one of two major players in the rapidly growing obesity drug market. Yet, the stock has lost half its value. 
Via The Motley Fool
New to Investing? These Are 3 Solid Blue Chip Stocks You Can Build Your Portfolio Around
Regardless of your investing knowledge or experience, you can't go wrong with these three behemoths in your portfolio. 
Via The Motley Fool
Topics Artificial Intelligence
1 Reason Eli Lilly (LLY) Is One of the Best Healthcare Stocks You Can Buy Today
Despite the company's run in recent years, it's not too late to buy. 
Via The Motley Fool
Independence Bank of Kentucky Buys Another $3.1 Million Eli Lilly (NYSE: LLY) Shares
Via The Motley Fool
Topics ETFs Regulatory Compliance
3 Healthcare Companies Insiders Are Buying
Insiders are buying these three healthcare companies that have catalysts to drive their share prices higher in the upcoming years. 
Via MarketBeat
Topics Initial Public Offering
FDA Approves Alzheimer’s Test Developed By Roche In Collaboration With Eli Lilly
The blood-based test is aimed at aiding the initial assessment for Alzheimer’s disease and other causes of cognitive decline in the primary-care setting in patients aged 55 and older. 
Via Stocktwits
Jim Cramer Declares Wall Street Divided: Three Distinct Markets Emerge
Wall Street, according to CNBC's Mad Money host Jim Cramer, is no longer a monolithic entity but rather a fractured landscape operating under three distinct economic realities. In recent broadcasts... 
Via MarketMinute
Topics Artificial Intelligence Economy
Recent Filing Shows That Sen. John Boozman Bought Over $49K Worth of iShares 7-10 Year Treasury Bond ETF Stock
 
Via Benzinga
Topics ETFs
Down 44%, Should You Buy the Dip on Viking Therapeutics?
The company is readying to take on pharma giants Novo Nordisk and Eli Lilly. 
Via The Motley Fool
Healthcare Opportunities And Risks Collide For Direxion's Eli Lilly-Focused ELIL, ELIS ETFs
 
Via Benzinga
This Stock Is Up By 285% This Year But Could Still Jump By 53%, According to Wall Street
Is it too late to get on the bandwagon? 
Via The Motley Fool
The Smartest Growth Stock to Buy With $100 Right Now
This beaten-down drugmaker is well positioned to turn things around. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.